36.6 F
New York
Thursday, April 22, 2021

AstraZeneca’s [NYSE: AZN] Lynparza Shows Positive Result In BRCA-Mutated Ovarian Cancer

Must read

Palantir [NYSE: PLTR] Recognized as a Crown Commercial Service supplier

Palantir Technologies Inc. has gained recognition as a supplier on the Crown Commercial Service (CCS) Back Office Software (BOS) RM6194 Framework. This award...

Trevena [NASDAQ: TRVN] Soar on Selection of TRV027in Global COVID-19 Trial

Shares of Trevena, Inc. skyrocketed more than 5 percent during the pre-market trading session of Wednesday. The strong performance of the firm indicated...

InfuSystem Announces Acquisition of OB Healthcare Corporation

InfuSystem Holdings Inc. disclosed Wednesday that it has bought OB Healthcare Corporation. As per the acquisition agreement, the firm has purchased the operating...

IAA [NYSE: IAA] Announces Expansion of Delivery Services in the UK

IAA, Inc. disclosed that its UK-based business unit has decided to expand its vehicle delivery services for its buyers. This expansion decision has...

AstraZeneca PLC [NYSE: AZN] revealed Friday that Lynparza has shown a long-term progression-free survival (PFS) benefit versus placebo in patients with newly diagnosed BRCA-mutated Ovarian Cancer.

If we look at the statistics of cancer, ovarian cancer is considered to be the eighth most common cause of death in women. In 2018, approximately 300,000 new patients have diagnosed with this disease and almost 185,000 have lost their lives.

Five-year follow-up data from the Phase III SOLO-1 trial has revealed that LYNPARZA decreased the risk of disease progression or death by 67%.

Shares of AstraZeneca traded up 1.47% as it gained +0.81 on Thursday. This company had recorded a trading volume of 3.99 million as compared to the average volume of 6.65 million.

Looking at its profitability, it has a return on assets (ROA) of 3.60%, returns on equity (ROE) is 17.80%. Its return on investment (ROI) is 8.30%.

If we turn our focus on its liquidity, it has a current ratio of 0.80. AstraZeneca market capitalization has remained high, hitting $148.04 billion at the time of writing.

In the past 52-weeks of trading, AZN has experienced the 52 weeks low range of $36.15 & a high range of $64.94. It has traded up 54.74% from its 52-weeks low and traded down -13.86% from its 52-weeks high.

If we look at the data of five years, the company has revealed that 48.3% of patients with the disease were treated with Lynparza have freed from the disease as compared to 20.5% on placebo.

More articles

Latest article

ICON [NASDAQ: ICLR] Secures Multiple Categories in 2021 CRO Leadership Awards

ICON Public Limited Company has disclosed that it has won multiple categories in the annual CRO Leadership Awards. This is another greatest achievement...

Equinox Announces Sale of Pilar Gold Mine

Equinox Gold Corp. revealed Monday that it has decided to sell its Pilar Gold Mine in Brazil to Pilar Gold Inc. The firm...

OpGen [NASDAQ: OPGN] Announces Strategic Collaboration New York State Department of Health

OpGen, Inc. revealed that it has entered into a strategic collaboration deal with the New York State Department of Health. The focus of...

Why Mer Telemanagement [NASDAQ: MTSL] Skyrocketed on Friday?

Shares of Mer Telemanagement Solutions Ltd skyrocketed during the trading session of Friday. The strong performance of the firm has indicated the positive...

Largo Resources Gets Approval for Listing on Nasdaq Stock Exchange

Largo Resources disclosed that it has finally obtained authorization from Nasdaq Stock Market LLC. As per the approval, the firm will now eligible to...

Aurora Mobile [NASDAQ: JG] Inks Agreement with Wanda Film

Aurora Mobile Limited disclosed Thursday that it has inked an agreement with Wanda Film Holding Co Ltd. Since its inception, Aurora Mobile has...

Brady [NYSE: BRC] Commence Tender Offer to Buy Nordic ID Oyj

Brady Corporation has inked an agreement with Nordic ID for its acquisition. The firm has commenced the tender offering to buy all the...

Cinedigm [NASDAQ: CIDM] Achieve Record Subscription and Ad-Supported User Growth Milestones

Shares of Cinedigm Corp. skyrocketed 19.30% after the firm reported the update about the subscription. The firm has achieved the best ever achievement...